Executive record

Lisa Rojkjaer

Director at RIGEL PHARMACEUTICALS INC

Follow
More
Challenge a Claim

Alpha ID: alpha:person:lisa-rojkjaerVersion: public-0As of: 2026-09-28

Not yet claimed7 published Claims3 sources
  • Director

Key Claims

Biography

Appointed EVP and Chief Medical Officer in March 2024, Dr. Rojkjaer most recently served as Chief Medical Officer of Sangamo Therapeutics and previously held CMO roles at Viracta Therapeutics and Nordic Nanovector, and served as Global Clinical Program Head at Novartis where she led development of Rydapt. She holds a Doctor of Medicine degree from the University of Toronto.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Executive career

  1. 2026 to end not publishedExecutive title: Executive Vice President and Chief Medical Officer · Organization not publishedRIGL DEF 14A executive officers

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. RIGL DEF 14A executive officers

    sec filing · Source published: Apr 3, 2026 · Retrieved: May 5, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 5, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 5, 2026
    • Executive company: Executive at RIGEL PHARMACEUTICALS INC · Claim reviewed: May 5, 2026
    • Executive title: Executive title: Executive Vice President and Chief Medical Officer · Claim reviewed: May 5, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 5, 2026

  2. Open source

    sec proxy · Source published: Apr 3, 2026 · Retrieved: Sep 2, 2026

    Supports 1 claim
    • Professional Role: Director at RIGEL PHARMACEUTICALS INC · Claim reviewed: May 5, 2026

  3. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of RIGEL PHARMACEUTICALS INC · Claim reviewed: May 5, 2026